FIELD: medicine, oncology. SUBSTANCE: composition has the following components per 1 mas. p. etoposide, mas. p.: polyvinylpyrrolidone 0.25-2.0; pharmaceutically acceptable solvent for etoposide 4-10, and water-soluble derivative of cellulose ether 0.0028-0.2. Etoposide amount is 10-20% of coposition mass. Preferably, composition has 5-70 mas. p. polyvinylpyrrolidone per 1 mas. p. water-soluble derivative of cellulose ether. Hydroxypropylcellulose can be used as water-soluble derivative of cellulose ether. Preferably, composition has, wt.-%: etoposide, 10-18; polyvinylpyrrolidone, 5-20; water-soluble derivative of cellulose ether, 0.05-2;, and polyethylene glycol, 60-80. The following composition is preferable, mas. p. : etoposide 1; polyvinylpyrrolidone 0.5-1; water-soluble derivative of cellulose ether, 0.01-0.1; and polyethylene glycol, 4.5-7. The following composition is preferable also, mas. p. per 1 mas. p. hydroxypropylcellulose: polyvinylpyrrolidone, 10-60; and polyethylene glycol, 70-300 at preferable molecular mass of polyethylene glycol 300-1000, at viscosity of 2% aqueous solution of hydroxypropylcellulose at 20 C - 3-500 Spoises. EFFECT: enhanced effectiveness of composition. 11 cl
